Significantly fewer thymic BCL11b-low patients remained in continuous complete remission at five years compared to BCL11b-high thymic T-ALL patients (at 5 yrs: Q1: n = 15, 38%; Q2-4: n = 78, 72%; P = 0.02; Additional file 1: Figure S2B). This evidence concerns the gene BCL11B and acute lymphoblastic leukemia.